Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YM060 (ramosetron) in diarrhea-predominant irritable bowel syndrome
2004-003880-61Phase 2Completed
- Sponsor
- Astellas
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ramosetron in Diarrhea-predominant irritable bowel syndrome (IBS-D) (4 arms), sponsored by Astellas. Primary endpoint: Responder rate of global assessment of relief of overall IBS symptoms. Started Dec 2004; status: completed.
02
Drugs
ramosetron
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on 2004-003880-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003880-61.